AIMOBIG (erenumab, genetical recombination) is a subcutaneous injection, 70 mg/1 mL (YJ code: 1190406G1029), used for the preventive treatment of migraine in adults. Manufactured by Amgen, it works by binding to the CGRP receptor to inhibit migraine-associated pain signals, typically administered once monthly as a 70 mg dose per 1 mL kit.
AIMOBIG subcutaneous injection 70 mg pen
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →
